SCHEMBL11989611

SCHEMBL11989611

CC(C)(C)C(C)(C)C(=O)NC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.56
PDK2 Q15119 1/20 0.56
PDK3 Q15120 1/20 0.56
PDK4 Q16654 1/20 0.56
SIGMAR1 Q99720 1/20 0.49
EPHX1 P07099 8/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
ALDH1A1 P00352 2/20 0.48
EPHX2 P34913 2/20 0.48
MAPT P10636 1/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP3A4 P08684 1/20 0.48
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11989610 0.98 PDK1 (0.59) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL18654098 0.89 PDK1 (0.63) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL9611267 0.82 ALDH1A1 (0.61) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL23481547 0.80 PDK1 (0.63) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL9611268 0.80 PDK1 (0.63) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL12206764 0.77 ALDH1A1 (0.61) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL942808 0.77 PDK1 (0.59) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL14243258 0.77 PDK1 (0.59) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL22110497 0.77 PDK1 (0.59) PDK1PDK2PDK3PDK4SIGMAR1
SCHEMBL21389434 0.77 PDK1 (0.55) PDK1PDK2PDK3PDK4SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247421-B2 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-21 US disclosed
US-20100189773-A1 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100189773-A1 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS MAP3K5, CDK5, MAP3K20 PDK1 147/4885PDK2 214/4885PDK3 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.